Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017. by DARCIS, Gilles et al.
1SCIentIfIC RePoRtS |  (2018) 8:8594  | DOI:10.1038/s41598-018-26852-0
www.nature.com/scientificreports
Factors associated with late 
presentation for HIV care in a single 
Belgian reference center: 2006–2017
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Françoise Uurlings1, Marianne Lecomte1, Philippe Léonard1, Jean-Baptiste Giot1, Karine 
Fombellida1, Dolores Vaira2 & Michel Moutschen1,2
Late presentation for HIV care is a major issue and the cause of higher morbidity, mortality and 
transmission. In this regard, we analyzed the characteristics of patients presenting for care at our center 
from January 2006 to July 2017 (n = 687). The majority of the studied population was of African origin 
(54.3%) with heterosexual women representing the main group (n = 292; 42.5%). 44% of the patients 
were late presenters (LP) (presenting for care with CD4 T cells <350/mm3 or an AIDS defining event) 
and 24% were late presenters with advanced disease (LP-AD) (presenting for care with CD4 T cells 
<200/mm3 or an AIDS defining event). A very high risk of being LP and LP-AD was associated with Sub-
Saharan origin (OR 3.4 and 2.6 respectively). Other factors independently associated with LP or LP-AD 
were age (OR 1.3), male gender (OR 2.0 and 1.5 respectively) and heterosexual route of transmission 
(OR 2.4 and 2.3 respectively). A significant increase in HIV screening without forgetting those groups 
would contribute to earlier HIV diagnosis, a key element to end the HIV epidemic. To achieve this goal, 
addressing the specific hurdles to HIV testing in the migrant population is critical.
Since a few years, the 90-90-90 target has become a central column of the worldwide pursuit to end the AIDS 
epidemic. The target reflects a fundamental shift in the world’s approach to HIV treatment towards the impor-
tance of maximizing viral suppression among people living with HIV1. Antiretroviral therapy (ART) is now rec-
ommended for all those with HIV infection in order to prevent AIDS-related illness and to decrease the risk of 
transmission.
Late presentation (LP) for care is a significant and persistent issue for the success of ART outcomes. Indeed, 
late presenters have an extended chance to transmit HIV while they are unaware of their HIV infection2–5. LP 
is also associated with a negative impact on mortality and morbidity6,7. Regarding to immunological recovery, 
patients who began ART with ≤350 CD4 T cells/mm3 generally do not regain normal CD4 naïve/memory T cell 
ratios8. The START trial clearly showed that the immediate initiation of antiretroviral therapy was superior to 
deferral of such therapy until the CD4 T cell count declined to 350 cells/mm3,9. A beneficial effect of immediate 
antiretroviral therapy was evident for both serious AIDS-related and serious non–AIDS-related events9, and the 
relative risk reduction was greatest among older participants, those with high plasma HIV RNA viral loads and 
with low baseline CD4 to CD8 ratios10.
Moreover, early initiation of ART restricts the establishment of the HIV reservoirs that are considered as a 
major barrier to the cure of HIV infection11,12. Early treatment not only reduces the size of the latent reservoir, but 
also alters the composition of the reservoir in a way that may enhance the efficacy of potential eradication ther-
apies13. Indeed, unless ART is started early, a large majority of latent viruses which constitute the HIV reservoir 
carries mutations that render infected cells insensitive to cytotoxic T lymphocytes (CTL)13.
Because of its many negative consequences for infected individuals and HIV transmission, it is critical to 
identify factors associated with late presentation for HIV care. The identification of those factors could indeed 
improve the effectiveness of HIV testing strategies with a focus on susceptible and possibly neglected groups.
A cross-European update from 34 countries on the prevalence and factors associated with LP has recently 
been published14. The huge number of patients included in this study allowed for an interesting and statisti-
cally significant analysis of factors associated with LP overtime. However, it highlighted also that there are major 
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differences between European regions, reducing the usefulness of such an analysis as the aim is to adapt the local 
testing strategies.
In this study, we conducted a rigorous analysis of factors associated with LP and LP with advanced dis-
ease (LP-AD) in a single Belgian reference center, with the ultimate objective to improve local early screening 
policies as well as in countries or regions around the world sharing similar epidemiologic and demographic 
characteristics.
Methods
Patients and definition of late presentation. This was a retrospective cohort study. People aged at least 
16 who presented for care (first clinic visit) at the Liege University Hospital (Belgium) between the 1st January 
2006 and 31 July 2017 were included in the study. Patients who had already received care for their HIV infection 
at another clinical center were excluded from the study as well as people already treated for more than one month 
before the first clinic visit. According to the consensus definition of LP15, patients who were previously diagnosed 
but who did not access to care were kept in the analysis. Indeed, the term ‘presentation for care’ means attendance 
at a health care facility that is able to monitor progression of HIV infection and initiate appropriate medical care. 
Diagnosis of HIV infection means presentation for care only if diagnosis of HIV infection is linked to appropriate 
access to care15. This information was obtained based on standardized procedure used to determine medical his-
tories at first presentation for care. Although it is not completely excluded that some patients presented for care 
in another center at an earlier time, we believe this approach is an effective and rigorous way to be in line with the 
LP definition15.
LP was defined as presentation for care with CD4 T cells <350/mm3 or an AIDS defining event (at any CD4 
T cell count) in the six months following first visit. LP with advanced HIV disease (LP-AD) was defined as pres-
entation for care with CD4 T cells <200/mm3 or an AIDS defining event (at any CD4 T cell count) in the six 
months following first visit. Seroconverters (negative HIV test over the past six months; n = 10) with CD4 T cell 
count <350/mm3 were moved from the LP or LP-AD groups to the non-LP group. By definition, such people are 
diagnosed soon after HIV infection, even if they have a low CD4 T cell count at HIV diagnosis. They would not 
have been reached by interventions that promote earlier targeted screening. Patients infected with HIV-2 were 
excluded from the analyses as kinetics of CD4 T cell count decrease might be different.
Information obtained at first clinic visit included date of birth, gender and geographical origin categorized as 
Belgium, Sub-Saharan Africa (SSA) and other to reflect the main group of immigrants in Belgium. HIV exposure 
group categorized as homo- bisexual, heterosexual, and other (including intravenous drug use (IDU)) was also 
collected. Participants with both sexual and IDU transmission risk (n = 5) were included in one of the sexual 
transmission groups.
Reported information finally included the screening context categorized as voluntary screening, medical con-
dition, refugee (defined as a person fleeing armed conflict or persecution and asking or benefiting from assistance 
by the state, the Red Cross or other organizations), incidental screening (for instance before a blood donation), 
pregnancy, HIV+ partner or other/unknown. Information regarding AIDS-defining illnesses and CD4 T cell 
count at first entry into care at the HIV clinic was available and was included in the analyses.
The Ethical Committee of the University Hospital of Liège approved the study protocol (reference 2018/118). 
Patients were informed of data collection by their treating physician and patients could object to further collec-
tion of clinical data according to an opt-out procedure. All patients included were assigned unique identification 
numbers to anonymize the data and protect confidentiality. All methods were carried out in accordance with 
relevant guidelines and regulations16.
Statistical analysis. Data were summarized as median and interquartile range (IQR) and extreme values for 
quantitative variables while frequency tables were used for the categorical findings. Multiple logistic regression 
was used to identify the impact of the patients’ characteristics on late presentation. Multiple imputation was used 
to replace missing values. Results were considered significant at the 5% critical level (p < 0.05). Data analysis was 
carried out using SAS (version 9.4 for Windows). R (version 3.2.5) packages were used for the figures.
Results
Of 759 patients who presented for care at the Liege University Hospital (Belgium) between the 1st January 2006 
and 31 July 2017, 68 were excluded because there was evidence that these people had been previously followed 
at another center or treated before. Patients infected with HIV-2 (n = 4) were excluded from the analyses (see 
Methods). The characteristics of the 687 remaining individuals who first presented for care are shown in Table 1. 
The median age is 34 years. 44.7% are female. The majority of the studied population is of African origin (54.3%). 
Heterosexual transmission was reported in 61.0% of the participants.
Among our 687 patient cohort, heterosexual women from SSA represented the main group (n = 292; 42.5%), 
which corresponds to the large majority of female patients (95.1%) and the heterosexual group (69.7%).
208 patients (30.3%) were Belgian men who have sex with men (MSM). Those patients represented nearly all 
the patients included in the homo/bisexual transmission group.
As indicated in Table 2, 44.0% of the patients were late presenters and 24.0% were late presenters with 
advanced disease. The variability of the LP and LP-AD percentages from one year to another, and according to the 
Belgian or migrant status, was not statistically significant (Fig. S1). In particular, there was no diminution of those 
percentages overtime. Supplementary Table 1 indicates the percentages of LP and LP-AD according to patients’ 
characteristics. The percentages of LP and LP-AD were higher in the groups of older individuals, in the female 
population, in the group of patients originating from SSA, in the heterosexual transmission group as well as in 
the group of refugees. In contrast, those percentages were lower in the patients diagnosed following a voluntary 
screening.
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Factors independently associated with late presentation and late presentation with advanced 
disease. Multiple logistic regression was used to measure the impact of the various patients’ characteristics, 
independently of one another, on late presentation and late presentation with advanced disease for HIV care.
Figure S2 and Table 3 present the adjusted odds ratios of being LP. Age (OR 1.3 (95% CI 1.1–1.5)), male gen-
der (OR 2.0 (95% CI 1.3–3.1)), Sub-Saharan origin (OR 3.4 (95% CI 1.9–5.9)) as well as heterosexual route of 
transmission (OR 2.4 (95% CI 1.4–4.1)) are factors associated with a statistically significant higher risk of being 
LP. Migrants from other parts of the world than SSA had also a higher risk of being LP (OR 1.9 (95% CI 1.0–3.4)). 
Refugees or individuals whose HIV diagnosis was made in the context of a medical condition presented a modest 
risk of being LP which did not reach statistical relevance.
Figure S3 and Table 4 present the adjusted odds ratios of being LP-AD. The same conclusions can be drawn 
for LP-AD as it did for LP. Indeed, Age (OR 1.3 (95% CI 1.1–1.5)), Sub-Saharan origin (OR 2.6 (95% CI 1.4–4.9)) 
as well as heterosexual route of transmission (OR 2.3 (95% CI 1.2–4.3)) were associated with a statistically rele-
vant higher risk of being LP-AD. Migrants from other parts of the world than SSA had also a higher risk of being 
LP-AD (OR 2.3 (95% CI 1.1–4.8)).
Individuals whose HIV diagnosis was made in the context of a medical condition presented a higher risk of being 
LP-AD (OR 2.1 (95% CI 1.3–3.6)). Refugees and male presented a higher risk of being LP-AD (OR 1.4 (95% CI 
0.78–2.4) and OR 1.5 (95% CI 0.93–2.3)) which did not reach statistical relevance, probably due to the sample size.
Discussion
Current guidelines indicate that ART should always be recommended irrespective of the CD4 T cell count, but the 
lower the CD4 T count, the greater the urgency to start ART immediately17. The use of ART is recommended at 
any CD4 T cell count mainly in order to reduce sexual transmission, the risk of AIDS event and mother-to-child 
transmission of HIV9. Early ART has also the potential benefits of reducing the severity of acute symptoms, 
lowering the viral load set-point and HIV reservoir size, reducing viral genetic evolution and the establishment 
N (%) Median (IQR) Extremes
Age (years) 687 34.0 (27.0–42.0) 16.0–68.0
Gender (Female) 307 (44.7)
Origin
   Belgium 238 (34.6)
   SSA 373 (54.3)
   Others 76 (11.1)
Mode of acquisition
   Heterosexual transmission 419 (61.0)
   Homo/Bisexual transmission 209 (30.4)
   Others or unknown 59 (8.6)
First CD4 T cell count
   Number/mm³ 687 386 (210–541) 0–1772
   <200/mm³ 155 (22.6)
   200–350/mm³ 150 (21.8)
   >350/mm³ 382 (55.6)
Context of the screening
   Incidental screening 45 (6.6)
   Voluntary screening 72 (10.5)
   Pregnancy 20 (2.9)
   HIV-positive partner 45 (6.6)
   Medical problem 198 (28.8)
   Refugee 225 (32.8)
   Unknown 82 (11.9)
Table 1. Characteristics of HIV patients included in the study, January 2006 to July 2017 (n = 687). SSA: Sub-
Saharan Africa. SD: standard deviation. IQR: Interquartile range.
N (%)
Non LP 385 (56.0)
LP(a) 302 (44.0)
LP-AD(b) 165 (24.0)
Table 2. Proportion of late presenters (LP) and late presenters with advanced disease (LP-AD) (N = 687). 
(a)CD4 T cells <350/mm3 or an AIDS defining event (at any CD4) in the six months following first visit. (b)With 
CD4 T cells <200/mm3 or an AIDS defining event (at any CD4) in the six months following first visit.
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of CTL escape mutation, decreasing immune activation and chronic inflammation and preserving immune func-
tion18,19. Early ART could possibly enhance post-treatment control and response to future eradication strate-
gies20,21. Consequently, the importance of early ART initiation has become increasingly evident in recent years.
In this context, analyzing the factors associated with a delayed presentation for care is certainly of importance. 
Several large studies have recently provided important data regarding to the risks of being LP and LP-AD14,22. 
However, these studies tend to erase the differences that exist between countries or regions and can potentially 
impact the factors associated with LP for HIV care. For instance, in our study, we showed that the majority 
(54.3%) of the studied population came from SSA. This particular characteristic of our cohort is certainly due to 
Belgian history, closely tied with several countries of SSA and in particular with Democratic Republic of Congo. 
In comparison, in a similar study recently performed in the neighboring Netherlands, the proportion on patients 
from SSA was only 15%23. In the COHERE cross-European study from 34 countries, the percentage of patients 
from SSA was only 8.7%14. Regional studies are thus needed in order to provide a more thorough analysis which 
will hopefully allow for a better HIV screening.
Of the 687 HIV patients included in our study between January 2006 and July 2017, 44% presented late and 
24% were late presenters with advanced disease. These proportions are comparable to the estimates published by 
others14,22–24. We did not observe any diminution of those percentages over time, showing that the efforts made 
during the last ten years to improve and increase HIV testing were insufficient to significantly decrease the num-
ber of late presenters.
We showed that factors associated with LP and LP-AD were age, male gender, migrant status as well as het-
erosexual route of transmission. Factors associated with LP and LP-AD were similar, which makes sense since 
LP-AD constitutes a sub-group of LP. Those factors have also been reported by others14,22–25.
Given the large proportion of migrants from SSA in our cohort (54.3%) and the associated very high risk to be 
late presenters or late presenters with advanced disease (OR 3.4 (95% CI 1.9–5.9) and 2.6 (95% CI 1.4–4.9) respec-
tively), this migrant population requires special attention. Although some patients in this group have acquired 
HIV in Africa and reached Belgium at an advanced stage of the disease, post-migration HIV acquisition is more 
frequent than previously thought. In a recent report by Alvarez-del Arco, the proportion of post-migration HIV 
acquisition within Europe was 63%26. The proportion of post-migration HIV acquisition was higher for Latin 
America and Caribbean migrants, and was also significant (45%) for people from SSA26. Migrant men who have 
Coefficient ± SE Odds ratio (95% CI) p-value
Intercept 21.6 ± 56.6 — —
Year of presentation for care −0.011 ± 0.028 1.0 (0.94–1.1) 0.69
Age (by 10 years older) 0.23 ± 0.084 1.3 (1.1–1.5) 0.0069
Sex (0 = Female, 1 = Male) 0.35 ± 0.11 2.0 (1.3–3.1) 0.0021
SSAa origin (0 = No, 1 = Yes) 0.61 ± 0.14 3.4 (1.9–5.9) <0.0001
Othera non belgian origin (0 = No, 1 = Yes) 0.31 ± 0.16 1.9 (1.0–3.4) 0.044
Hetetosexualb mode of acquisition (0 = No, 1 = Yes) 0.43 ± 0.14 2.4 (1.4–4.1) 0.0024
Other (non sexual) mode of acquisition (0 = No, 1 = Yes) 0.11 ± 0.26 1.2 (0.45–3.4) 0.68
Context of screening = Refugee (0 = No, 1 = Yes) 0.12 ± 0.12 1.3 (0.78–2.1) 0.34
Context of screening = Medical problem (0 = No, 1 = Yes) 0.17 ± 0.11 1.4 (0.90–2.2) 0.14
Context of screening = Voluntary screening (0 = No, 1 = Yes) −0.036 ± 0.14 0.93 (0.53–1.6) 0.81
Table 3. Factors associated with late presentation (LP) – Multiple logistic regression (N = 687). aRef = Belgian. 
bRef = Homo/bisexual transmission. SSA: Sub-Saharan Africa. SE: standard error. CI: confidence interval. 
Bolded data are statistically relevant (p < 0.05).
Coefficient ± SE Odds ratio (95%IC) p-value
Intercept 11.5 ± 64.6 — —
Year of presentation for care −0.0066 ± 0.032 1.0 (0.93–1.1) 0.84
Age (by 10 years older) 0.24 ± 0.095 1.3 (1.1–1.5) 0.011
Sex (0 = Female, 1 = Male) 0.19 ± 0.12 1.5 (0.93–2.3) 0.10
SSAa origin (0 = No, 1 = Yes) 0.47 ± 0.16 2.6 (1.4–4.9) 0.0036
Othera non belgian origin (0 = No, 1 = Yes) 0.42 ± 0.18 2.3 (1.1–4.8) 0.023
Hetetosexualb mode of acquisition (0 = No, 1 = Yes) 0.41 ± 0.16 2.3 (1.2–4.3) 0.013
Other (non sexual) mode of acquisition (0 = No, 1 = Yes) 0.27 ± 0.30 1.7 (0.54–5.5) 0.36
Context of screening = Refugee (0 = No, 1 = Yes) 0.16 ± 0.14 1.4 (0.78–2.4) 0.27
Context of screening = Medical problem (0 = No, 1 = Yes) 0.38 ± 0.13 2.1 (1.3–3.6) 0.0062
Context of screening = Voluntary screening (0 = No, 1 = Yes) −0.11 ± 0.19 0.81 (0.38–1.7) 0.59
Table 4. Factors associated with late presentation with advanced disease (LP-AD) – Multiple logistic regression 
(N = 687). aRef = Belgian. bRef = Homo/bisexual transmission. SSA: Sub-Saharan Africa. SE: standard error. CI: 
confidence interval. Bolded data are statistically relevant (p < 0.05).
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sex with men appear at particular risk of HIV acquisition post-migration as supported by the frequent acquisition 
of viral clades not prevalent in native countries27. In our cohort however, the majority of patients from SSA were 
heterosexual women who represented 42.5% of the total studied population. Interestingly, in a French report by 
Desgrées-du-Loû and colleagues, it was estimated that at least 30% of HIV-infected women born in SSA acquired 
HIV while living in France28. More recently, Pannetier et al. showed that sub-Saharan African women living in 
the Paris region were regularly exposed to non-consensual sex (NCS) forced sex in their lifetimes29. They further 
provided evidence of an association between NCS after migration and post-migration acquisition of HIV among 
sub-Saharan African migrant women29. Those reports clearly highlight the need for primary prevention programs 
targeting these communities. Improving access to HIV testing and treatment for all infected persons, irrespective 
of their immigration status, could certainly impact on reducing incidence of late presentation and infection rates 
both within and beyond migrant communities. This would impose addressing the numerous hurdles to HIV 
screening and care in migrant communities, including cultural and linguistic barriers, racism and xenophobia as 
well as stigma from their communities30.
We further showed that age, male gender and heterosexual route of transmission are independent factors asso-
ciated with LP and LP-AD. Indeed, people who are more likely to be diagnosed and to present late usually do not 
consider themselves as “risk categories”. HIV screening procedures basically depend on an individual’s perception 
of his/her HIV risk. For instance, MSM have a lower risk of being LP in our analysis, most likely because they 
better perceive the risk of being infected by HIV.
Additionally, healthcare providers may consider HIV testing less often in individuals who are not perceived 
as being at high risk of HIV such as older individuals or heterosexuals, leading to missed opportunities for HIV 
diagnosis. High rates of missed opportunities for HIV diagnosis have previously been reported, highlighting the 
ongoing need for physician education on HIV testing and clinical signs suggestive of HIV infection31,32. This is 
particularly relevant for people aged 50 years since this group would benefit most from immediate initiation of 
ART as recently shown in a post-hoc subgroup analysis of the START trial10.
Late presentation for HIV remains a key unresolved issue with severe consequences at the individual, soci-
etal and economic levels33. As underlined by our work, information campaigns and more effective HIV testing 
strategies are needed to shrink the inadmissibly high rates of late presentation for HIV care. All age and risk 
groups have to be targeted for HIV testing. Voluntary testing has to be encouraged through education campaigns 
targeting high prevalence groups but also neglected groups with a higher risk of LP. The education of healthcare 
providers should also emphasize the importance of a widespread HIV testing.
Most importantly in the context of a large population from SSA, it is critical to address the identified blocks 
to HIV testing and HIV care in migrant communities. This will hopefully result in improved treatment outcomes 
and may reduce HIV transmission, a necessary step forward a better control of AIDS epidemic.
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